Anti-FDFT1 antibody [EPR16481] - BSA and Azide free

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

FDFT1 also known as squalene synthase catalyzes the first committed step in cholesterol biosynthesis. This enzyme functions as a dimer and has a molecular weight of approximately 47 kDa. FDFT1 is widely expressed in the liver where cholesterol synthesis primarily occurs but you can also find it present in many tissues throughout the body. As a membrane-bound protein it anchors to the endoplasmic reticulum where it carries out its enzymatic role.

Biological function summary

FDFT1 facilitates the conversion of farnesyl diphosphate to squalene a critical precursor in sterol and cholesterol synthesis. This enzyme does not work in isolation but acts as a part of the larger sterol biosynthesis pathway. The activity of FDFT1 aligns with key metabolic demands particularly in tissues with high rates of cell division or hormone production making it essential for maintaining cellular sterol homeostasis.

Pathways

FDFT1 is an important enzyme in the mevalonate pathway and cholesterol biosynthesis pathway. This enzyme interacts closely with proteins such as HMG-CoA reductase and lanosterol synthase which are pivotal in these pathways. This relationship ensures the proper flow from acetyl-CoA to cholesterol and other isoprenoids critical for cell membrane integrity and signaling functions.

Associated diseases and disorders

Disruptions in FDFT1 activity can lead to conditions like hypercholesterolemia and related cardiovascular diseases. Excess or deficiency in its function impacts cholesterol levels directly making it a target for cholesterol-lowering therapies. FDFT1's activity also connects to the proteins NPC1 and LDL receptor which play a role in cholesterol transport and uptake further linking it to pathways that contribute to atherosclerosis when dysregulated.